Mechanism of Action
Membrane and Intracellular Mechanisms
Omiganan shares the dual mechanism of its parent indolicidin: at lower concentrations it permeabilizes bacterial membranes without full lysis, while at higher concentrations it causes rapid membrane disruption. The modified tryptophan-rich sequence maintains the membrane-active properties of indolicidin while an engineered arginine composition improves the charge-driven membrane targeting. In acne, the anti-Cutibacterium acnes (formerly P. acnes) activity is combined with anti-inflammatory properties relevant to inflammatory acne pathology.
Anti-inflammatory Properties
Beyond direct antimicrobial killing, omiganan modulates Toll-like receptor (TLR) signaling and reduces inflammatory cytokine production in keratinocytes. This dual antimicrobial-anti-inflammatory profile is relevant for acne and rosacea, where both bacterial colonization and dysregulated inflammation drive pathology. The mechanism distinguishes omiganan from purely antimicrobial agents.
Research Summary
Acne Vulgaris Phase 3
Phase 3 (Completed, No Approval)NovaBay Pharmaceuticals conducted Phase 3 trials of omiganan 1% gel for acne. Results showed reduction in inflammatory lesion counts but did not consistently meet FDA-specified endpoints (Investigator Global Assessment success). The trials highlighted challenges of acne as a regulatory endpoint where placebo response rates are high and the FDA demanded specific responder criteria that were not met. NovaBay discontinued development due to these regulatory challenges, not fundamental safety concerns.
Catheter-Site Infection Prevention
Phase 3 (Completed)Omiganan 1% topical solution was evaluated in Phase 3 for prevention of catheter-associated bloodstream infections in ICU patients. Results were mixed, reduction in catheter colonization but not a statistically significant reduction in bloodstream infections in the primary analysis. The secondary analysis showed benefit in a pre-specified subgroup, but this was insufficient for FDA approval. Catheter colonization data supported the antimicrobial mechanism in humans.
Calculate your Omiganan dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Acne vulgaris (Phase 3) | 1% gel twice daily | Twice daily x 12 weeks | Topical |
| Catheter site (Phase 3) | 1% solution daily | Daily catheter site application | Topical |
Not approved. Multiple Phase 3 trials completed without FDA approval. Rosacea Phase 2b data positive.
Interactions
Safety Profile
Omiganan was well tolerated across all Phase 3 programs. Local skin irritation was minimal. No systemic absorption detected at therapeutic topical doses. No resistance development observed in treated patients over the course of the trials. The multiple Phase 3 programs established a strong safety database without serious adverse events related to omiganan.
References
- [1]Fritsche TR, et al. (2008). In vitro activity of omiganan pentahydrochloride against recent bacterial isolates. Diagn Microbiol Infect Dis, 60(1), 1-9.
- [2]Melo MN, et al. (2009). Antimicrobial peptides: linking partition, activity and high membrane-bound concentrations. Nat Rev Microbiol, 7(3), 245-250.